Paul Hudson

Chief Executive Officer, Sanofi

Joined Sanofi, a global biopharmaceutical company dedicated to transforming scientific innovation into healthcare solutions, as Chief Executive Officer in September 2019. Over 25 years’ experience driving growth and building strong teams for numerous pharmaceutical companies across the United States, Asia and Europe. Starting as a sales representative and ascending to Chief Executive Officer of Novartis Pharmaceuticals before joining Sanofi; known for identifying medicines that can change patients’ lives and commercializing them to full potential. Drove the success of Entresto and the development of Cosentyx, a top-selling treatment of Novartis. Also extended AstraZeneca’s footprint in the oncology field with cancer drugs Tagrisso and Lynparza. Close ties with global innovation hubs led to early adoption of digitization to empower and accelerate R&D while increasing productivity across business functions. Degree in economics; Diploma, Chartered Institute of Marketing. Honorary Doctor of Business Administration, Manchester Metropolitan University. Member of the Board of PhRMA.

最热内容

全球合作

増加する交通事故による死者数、企業が取るべき対策とは

現在、世界では交通事故による死傷者が急増しており、年間の死者数は130万人、負傷者数は5,000万人に達しています。これは、交通インフラの老朽化、携帯電話などの使用による運転中の注意力散漫、新しい種類のモビリティの登場、自動車台数が過去最大に増加していることなどが影響しています。

2023年09月11日

关于我们

加入我们

  • 登录
  • 成为我们的合作伙伴
  • 成为我们的会员
  • 订阅我们的新闻稿
  • 联系我们

快捷链接

语言版本

隐私政策和服务条款

站点地图

© 2025 世界经济论坛